Nevertheless, a phase I trial of pinometostat, a small-molecule DOT1L inhibitor, conducted in children with r/r MLL-associated AML (NCT02141828) demonstrated only a transient reduction in leukemic blast counts [54]. Here, KMT2A is linked to acute myeloid leukemia.